Citation only
via OpenAlex
Abstract 13927: AAV Gene Therapy to Treat Underlying Cardiac Biomechanical Defects in Lmna Dilated Cardiomyopathy Improves Lifespan and Preserves Ejection Fraction in Lmna DCM Mouse Model
Hendrikje Werner, Esther Shuyi Gan, Connie Y Loh, Nyein Thet Khaing, Jinqiu Zhang, Mervyn Ong, Brian E. Burke, Yann Chong Tan, Colin L. Stewart, Yin Loon Lee
Circulation · 2022 · ▲ 3 citations
Abstract
Mutations in the LMNA gene are the second most common cause of genetic dilated cardiomyopathies (DCMs) with a prevalence of ~1/12500. Adeno-associated virus (AAV) gene therapies are a promising treatment modality for genetic disease. However, the autosomal dominant, gain-of-function mutations underlying LMNA DCM preclude standard gene replacement approaches. To understand LMNA DCM, we previously generated a mouse model that exhibits reduced ejection fraction, dilation of ventricular inner dimensions and increased cardiac fibrosis, surviving for only ~40 days after cardiac-specific deletion of the Lmna gene. We propose that the mutant LMNA gene weakens the structural integrity of the nucleus, making it vulnerable to biomechanical forces generated by contracting cardiomyocytes, which ultimately results in nuclear damage and a decline in cardiac function. Our gene therapy, AAV9-cTnT-GSLA01, prevents nuclear damage and disease in our Lmna DCM model by reducing biomechanical forces transmitted to the nucleus. To determine if we can treat, rather than prevent, Lmna DCM, we injected animals with AAV9-cTnT-GSLA01 at 1x10 14 vg/kg at different timepoints (21, 17, 14 and 1 day(s)) after induction of Lmna deletion. Treatment with AAV9-cTnT-GSLA01 17 days post Lmna deletion resulted in lifespan extension to 108 days (P= 0.0002), while earlier intervention at day 14 or day 1, improved lifespan to 122 and 208 days respectively (P = 0.0002, P= 0.0035). To address dose dependency of AAV9-cTnT-GSLA01, we delivered the vector at 5x10 13 vg/kg, 1x10 14 vg/kg, and 2x10 14 vg/kg at 17 days after Lmna deletion. Lifespan was extended from 40 days in untreated mice to 51.5 (P = 0.0135), 67.5 (P < 0.0001), and 103.5 days (P < 0.0001) respectively. The progressive decline of ejection fraction in these mice was attenuated in a dose-dependent manner. Thus, the positive effect of AAV9-cTnT-GSLA01 on lifespan and cardiac function in Lmna DCM mice is enhanced with increasing dose and transgene expression. Initial optimisation of the therapeutic expression cassette appears to improve lifespan extension significantly. AAV9-cTnT-GSLA01 is a novel gene therapy approach that promises to address the underlying cause of LMNA DCM.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1161/circ.146.suppl_1.13927
- Canonical
- link ↗
- Fetched
- 2026-10-13 MST
Cite this
APA
Werner, H., Gan, E.S., Loh, C.Y., Khaing, N.T., Zhang, J., Ong, M., Burke, B.E., Tan, Y.C., Stewart, C.L., & Lee, Y.L. (2022). Abstract 13927: AAV Gene Therapy to Treat Underlying Cardiac Biomechanical Defects in Lmna Dilated Cardiomyopathy Improves Lifespan and Preserves Ejection Fraction in Lmna DCM Mouse Model. <em>Circulation</em>. https://doi.org/10.1161/circ.146.suppl_1.13927
Vancouver
Werner H, Gan ES, Loh CY, Khaing NT, Zhang J, Ong M, et al. Abstract 13927: AAV Gene Therapy to Treat Underlying Cardiac Biomechanical Defects in Lmna Dilated Cardiomyopathy Improves Lifespan and Preserves Ejection Fraction in Lmna DCM Mouse Model. Circulation. 2022. doi:10.1161/circ.146.suppl_1.13927.
BibTeX
@article{hendrikje2022Abstra,
title = {Abstract 13927: AAV Gene Therapy to Treat Underlying Cardiac Biomechanical Defects in Lmna Dilated Cardiomyopathy Improves Lifespan and Preserves Ejection Fraction in Lmna DCM Mouse Model},
author = {Hendrikje Werner and Esther Shuyi Gan and Connie Y Loh and Nyein Thet Khaing and Jinqiu Zhang and Mervyn Ong and Brian E. Burke and Yann Chong Tan and Colin L. Stewart and Yin Loon Lee},
journal = {Circulation},
year = {2022},
doi = {10.1161/circ.146.suppl_1.13927},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Human Molecular Genetics 2017
Open access · OA
Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID
Hypertension 2002
Citation only
In Vivo klotho Gene Transfer Ameliorates Angiotensin II-Induced Renal Damage
Aging cell 2026
Open access · OA
TRF2 Recovers Ischemic Postconditioning Cardioprotection in Aged Myocardiocytes by Regulating CSNK2A2 Localization and FUNDC1 Dephosphorylation.
International Journal of Molecular Sciences 2021
Open access · CC-BY
NMRK2 Gene Is Upregulated in Dilated Cardiomyopathy and Required for Cardiac Function and NAD Levels during Aging
2026
Preprint
Acarbose improves cognitive function in a mouse model of normal aging but not Alzheimer’s disease
bioRxiv (Cold Spring Harbor Laboratory) 2021
Preprint · OA